These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16485550)

  • 1. [Novel NMP22 quick qualitative analysis (BladderChek NMP22) for the diagnosis of urothelial tumor].
    Minagawa T; Nishizawa S; Kamigaito T; Okaneya T
    Nihon Hinyokika Gakkai Zasshi; 2006 Jan; 97(1):20-6. PubMed ID: 16485550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
    Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
    Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
    Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
    Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
    Xia CS; Fan CH; Su M; Wang QS; Bao HZ
    Dis Markers; 2020; 2020():3424039. PubMed ID: 32454904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
    Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
    Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
    Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
    Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
    Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
    Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
    Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
    Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
    Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma.
    Li HX; Wang MR; Zhao H; Cao J; Li CL; Pan QJ
    Diagn Cytopathol; 2013 Oct; 41(10):852-7. PubMed ID: 23444210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma].
    Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M
    Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
    Tomera KM
    Expert Rev Mol Diagn; 2004 Nov; 4(6):783-94. PubMed ID: 15525221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.
    Lee MY; Tsou MH; Cheng MH; Chang DS; Yang AL; Ko JS
    World J Urol; 2000 Dec; 18(6):401-5. PubMed ID: 11204258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
    Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
    Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.